CoChat

The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Introduction Recently, the European Medicines Agency (EMA) received reports of suicidal thoughts and self-injury associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) liraglutide and semaglutide. Research design and methods Herein, we sought to evaluate suicidality associated with all GLP-1 RAs relative to other glucose-lowering agents currently approved by the United States Food and Drug Administration (FDA). Reports of suicidal ideation, "depression/suicidal", suicidal behavior, suicidal attempts, and completed suicide associated with GLP-1 RA exposure reported to the FDA between 2005 and October 2023 were obtained from the FDA Adverse Event Reporting System (FAERS). We present data using the reporting odds ratio (ROR). The ROR was considered significant when the lower limit of the 95% confidence interval (CI) was greater than 1.0. Results Disproportionate reporting of suicidal ideation and "depression/suicidal" was observed with semaglutide and liraglutide. Disproportionate reporting of suicidal behavior, suicide attempts, and completed suicide was not observed for any of the FDA-approved GLP-1 RAs. Conclusions Using the Bradford Hill criteria, however, and taking into consideration confounders, no causal link between GLP-1 RAs and suicidality exists.

Overview

Integrity signals

Registry

Crossref · 10.1080/14740338.2023.2295397

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 25 references

Research works printed but not linked: 1

  1. Tenny S, Hoffman MR. Odds ratio. St. Petersburg (Florida): StatPearls Publishing; 2023.

Cited by

See all 126

Metadata

Authors
McIntyre, R. S., Mansur, R. B., Rosenblat, J. D., & Kwan, A. T. H.
Affiliations
  • University of Toronto (CA)
  • University Health Network (CA)
  • University of Ottawa (CA)
Corresponding author
McIntyre, Roger S.
Venue
Expert Opinion on Drug Safety
Published
2023-12-19
Volume
23
Issue
1
Pages
47-55
ISSN
  • 1474-0338 (ISSN-L)
  • 1744-764X
OpenAlex
W4389681767
Cited by
126
References
25
Citations by year
2026: 31 · 2025: 52 · 2024: 43
FWCI
22.35
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Drug Safety (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
GLP-1 receptor agonists, suicidality, liraglutide, semaglutide, suicidal ideation, adverse drug reactions, drug safety, reporting odds ratio, suicide mortality
MeSH terms
Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Suicide, United States, United States Food and Drug Administration, Glucagon-Like Peptide 1, Suicidal Ideation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS). https://app.cochat.ai/papers/10.1080/14740338.2023.2295397
The paper
McIntyre, R. S., Mansur, R. B., Rosenblat, J. D., & Kwan, A. T. H. (2024). The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2023.2295397

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.